Management of ER+ Postmenopausal Early Breast Cancer

CCO's expert faculty members present compelling clinical data on the use of predictive factors for guiding treatment decisions for breast cancer patients as well as therapeutic strategies and safety profiles associated with the use of tamoxifen and aromatase inhibitors.

CME-Certified Virtual Presentations:

The Role of Predictive Factors in Guiding Treatment Decisions for ER-Positive Postmenopausal Breast Cancer William J. Gradishar, MD, FACP, reviews predictive factors and prognostic assays used to stratify postmenopausal patients with early breast cancer and guide treatment decisions.   Downloadable slideset

Current Hormonal Therapy Strategies for ER-Positive Postmenopausal Breast Cancer Ruth M. O’Regan, MD, reviews the clinical management of postmenopausal patients with early breast cancer receiving hormonal therapy.    Downloadable slideset

Evaluating Long-Term Safety of Aromatase Inhibitors Paul E. Goss, MD, PhD, FRCPC, FRCP, reviews the long-term safety profiles of tamoxifen and aromatase inhibitors for the treatment of postmenopausal patients with early breast cancer. Downloadable slideset

Management of ER+ Postmenopausal Breast Cancer Harold J. Burstein, MD, PhD, explores treatment options for adjuvant therapy for postmenopausal women with early stage breast cancer.

CME-Certified Modules:

The Role of Predictive Factors in Guiding Treatment Decisions for Estrogen Receptor–Positive Postmenopausal Breast Cancer William Gradishar, MD, FACP, explores the use of gene signature assays and other prognostic tools to optimize treatment strategies for postmenopausal breast cancer patients.

Current Hormonal Therapy Strategies for Estrogen Receptor–Positive Postmenopausal Breast Cancer Ruth M. O’Regan, MD

Evaluating Long-Term Safety of Aromatase Inhibitors Paul E. Goss, MD, PhD, FRCPC, FRCP, reviews the safety profiles associated with the long-term use of aromatase inhibitors.

Optimizing Treatment Choices in Ovarian Cancer

Through 3 CME-certified Virtual Presentations, CCO's expert faculty members discuss current clinical management strategies for recurrent/refractory ovarian cancer, including risk factors, screening, surgery, and current and novel agents. Associated downloadable slidesets are available for use in your own presentations.

CME-Certified Virtual Presentations:

Early Detection and Treatment of Ovarian Cancer Judith K. Wolf, MD, discusses risk factors, screening strategies, and prophylactic surgery in the setting of ovarian cancer.   Downloadable slideset

Current Controversies in the Management of Recurrent Ovarian Cancer Robert F. Ozols, MD, PhD, discusses current clinical management strategies for patients with recurrent ovarian cancer.  Downloadable slideset

New Agents for the Management of Ovarian Cancer Bradley J. Monk, MD, discusses new agents and strategies for the clinical management of patients with ovarian cancer.   Downloadable slideset

Novel Approaches in Frontline Multiple Myeloma Therapy: Understanding the Options and Implications for Transplantation

Through a CME-certified educational module and 3 Interactive Case Challenges, CCO's expert faculty members explore recent thinking regarding frontline therapy of multiple myeloma.

CME-Certified Module and Downloadable PowerPoint Slideset:

CME-Certified Interactive Case Challenges: 

Coming Soon!

Clinical Issues and Future Directions in Hematologic Malignancies

Through 6 CME-certified Virtual Presentations, CCO’s expert faculty discuss new data presented at the 2007 Hematology meeting regarding multiple myeloma, non-Hodgkin’s lymphoma, acute leukemias, myelodysplastic syndrome, chronic myeloid leukemia, and chronic lymphocytic leukemia. The accompanying downloadable slidesets can be used for further study or in your own presentations.

Now Available!

CME-Certified Virtual Presentations and Downloadable PowerPoint Slidesets:

	Multiple Myeloma Amitabha Mazumder, MD, discusses new data in multiple myeloma presented at the 2007 hematology meeting.          Downloadable Slideset
	Non-Hodgkin’s Lymphoma Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkin’s lymphoma.          Downloadable Slideset
	Acute Leukemias Farhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding acute leukemias.            Downloadable Slideset
	Myelodysplastic Syndrome     Allen S. Yang, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with myelodysplastic syndrome.          Downloadable Slideset
	Chronic Myeloid Leukemia       Neil Shah, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with chronic myeloid leukemia.          Downloadable Slideset
	Chronic Lymphocytic Leukemia       Michael J. Keating, MB BS, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia.          Downloadable Slideset

2008 American Society of Clinical Oncology Annual Meeting

CCO's independent coverage of the 2008 Clinical Oncology meeting includes Capsule Summaries of key presentations, as well as Expert Analyses, Expert Recaps, and brief video Expert Highlights that focus on key issues highlighted at the conference.

• Breast Cancer
  William J. Gradishar, MD; FACP Clifford A. Hudis, MD; and Kathy D. Miller, MD
  
  
• Gastrointestinal Cancers
  Axel Grothey, MD; John L. Marshall, MD; and Richard M. Goldberg, MD
  
  
• Genitourinary Cancers
  Brian I. Rini, MD; David I. Quinn, MD, PhD; and Nicholas J. Vogelzang, MD
  
  
• Hematologic Malignancies
  Andre Goy, MD, MPH; Hagop M. Kantarjian, MD; and Sagar Lonial, MD
  
  
• Lung Cancer
  David R. Gandara, MD; Thomas J. Lynch, MD; and Alan B. Sandler, MD
  
  
• Ovarian Cancer
  Coming Soon!

Download short video and audio reviews of key treatment areas by Ramaswamy Govindan, MD; Kathy D. Miller, MD; Richard M. Goldberg, MD; Brian I. Rini, MD; and Hagop Kantarjian, MD.

Attacking the Signal at the Switch: Unraveling the Mysteries of mTOR Inhibition in Multiple Tumor Types

Through 5 CME-certified educational modules, CCO's expert faculty members explore the rationale for mTOR inhibition as an approach to cancer therapy, review the latest trial results in renal cell carcinoma and other solid tumors and hematologic cancers, and discuss how mTOR inhibitors may be integrated into current treatment regimens.

Now Available!

CME-Certified Modules:

Master Class in Management of Liver Metastases From Colorectal Cancer: Case-Based Learning

Now Available!

Virtual Presentation:

CCO Slideset:

Treatment Challenges in Myelodysplastic Syndromes

Through a CME-certified educational module and Interactive Case Challenges, CCO's expert faculty members review the latest data on the treatment of myelodysplastic syndromes and explore realistic clinical situations.

CME-certified Module:

• Insights Into the Pathogenesis, Classification, and Treatment of Myelodysplastic Syndromes
  Alan F. List, MD, reviews current clinical trial data regarding the clinical management of patients with MDS.
  

CME-certified Case Challenges:

• Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic Syndrome
  In this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7.
  
• Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic Syndrome
  Alan F. List, MD, reviews treatment options for a patient with del(5q) MDS.
  
• Coming Soon!
  Treatment of a 52 Year-Old Man with High-Risk MDS
  Charles A. Schiffer, MD

2008 Genitourinary Cancers Symposium

Nicholas J. Vogelzang, MD, and David I. Quinn, MD, discuss the most important clinical data presented at the 2008 Genitourinary Cancers Symposium, including recent findings on prevention, screening, diagnosis, treatment approaches, and current controversies in the management of cancers of the prostate, kidney, bladder, and testes.

CME-Certified Module:

• Conference Report: Prostate, Renal Cell, and Bladder Cancer
  David I. Quinn, MD, PhD and Nicholas J. Vogelzang, MD

Practical Answers to Key Clinical Challenges: Optimizing Patient Outcomes in Breast Cancer

In this CME-certified educational module based on the results of a readership survey, Kathy S. Albain, MD; Kathy D. Miller, MD; Hope S. Rugo, MD; and Linda T. Vahdat, MD, discuss breast cancer cases and optimal treatment regimens for patients in the adjuvant, neoadjuvant, and metastatic settings. A downloadable slideset accompanies the module.

Click here to begin.

2008 Gastrointestinal Cancers Symposium

CCO's independent coverage of the 2008 Gastrointestinal Cancers Symposium includes 3 CME-certified Conference Reports and an accompanying downloadable slideset focusing on key presentations at the conference.

Melanoma Treatment Update

Through 4 CME-certified educational modules, CCO’s expert faculty members review the latest data on the treatment of melanoma.

Genetics and Molecular Pathogenesis of Melanoma: Current Understanding

Diagnosis and Staging of Melanoma: Evolving Practice

Treatment of Melanoma: Current Best Practice

Exploring New Directions in Melanoma Treatment

6th International Symposium on Translational Research in Oncology

Through 8 CME-certified slidesets, CCO's expert faculty members, including Program Directors Dennis J. Slamon, MD, PhD, and John Crown, MD, MPH, review the latest data based on translational research in oncology that were presented at the International Translational Research in Oncology meeting held in Dublin, Ireland, in October 2007.

• Session I: Growth Factors and Growth Factor Receptors
• Session II: Steroid Hormonal Receptors and Their Manipulation
• Session III: Apoptosis and Programmed Cell Death
• Session IV: Malignant Angiogenesis and Antiangiogenic Therapies
• Session V: Signal Transduction: Targets in the Malignant Signaling Process
• Session VI: Immunotherapies and Vaccine Strategies
• Session VII: Malignant Stem Cells as Targets in Oncology
• Session VIII: New Approaches to Pathway Identification, Predictive/Prognostic Factors, and Biologic imaging
  

Hematologic Malignancies Volume 2, Issue 1, 2007

• Maintenance Therapy With Thalidomide in Patients With Multiple Myeloma by Sagar Lonial, MD
  
• Bortezomib in the Treatment of Patients With Waldenström's Macroglobulinemia by Steven P. Treon, MD, MA, PhD
  
• Magnetic Resonance Imaging vs Metastatic Bone Survey for the Detection of Focal Lesions in Patients With Multiple Myeloma by Noopur Raje, MD
  
• Significance of Complete Responses After Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma by Craig H. Moskowitz, MD
  
• Lenalidomide Shows High Response Rate in Patients With Relapsed or Refractory B-Cell CLL by Bruce D. Cheson, MD

Advances in Metastatic Colorectal Cancer: Molecular Pathways, Biomarkers, and Clinical Results

This series of CME-certified Expert Recaps and accompanying downloadable slidesets provides a comprehensive update on the use of targeted treatments and biomarkers to optimize patient outcomes in metastatic colorectal cancer. Developed with Clinical Care Options' expert faculty members, these slidesets are available for use as a self-study resource or in your own presentations.

• Tumor Immunology: Treatment Approaches With Immunotherapies in Human Cancer
  Review 3 CME-certified modules and a downloadable slideset.
  
  
• Advances in the Treatment of Lymphoproliferative Malignancies: Promising Directions in Mantle Cell Lymphoma, Follicular Lymphoma, and Waldenstrom’s Macroglobulinemia
  Access 4 interactive modules and downloadable slidesets.
  
  
• Optimal Treatment of Locally Advanced/Metastatic Pancreatic Cancer: Current Progress and Future Challenges
  This series includes 2 CME-certified didactic modules and a downloadable slideset.
  
  
• Anthracyclines in the Treatment of Multiple Myeloma: Traditional and Evolving Roles
  Through a CME-certified educational module, CCO's expert faculty review the use of anthracyclines in the treatment of patients with multiple myeloma and help you to apply this information in real-world scenarios through CME-certified interactive case challenges.
  
  
• Imatinib Resistance in the Treatment of Chronic Myeloid Leukemia: Current Management Options and Emerging Therapies
  In this CME-certified educational module, Elias Jabbour, MD; Jorge E. Cortes, MD; and Hagop M. Kantarjian, MD, discuss current and evolving treatments for chronic myeloid leukemia.
  
  
• Proceedings of the 17th International Prostate Cancer Update Meeting
  Noted experts in the field of prostate cancer put the latest findings from this meeting in perspective.
  
  
• Treatment Advances in Multiple Myeloma: Management of Challenging Clinical Scenarios
  This series includes 2 interactive cases that test your ability to manage patients and give you the opportunity to compare your answer with that of others who have taken the test. Be sure to read the introductory educational module for the latest thinking on treatment in this rapidly changing field.
  
  
• Navigating Multiple Pathways: Evolving Options and Future Directions in Targeted Therapies
  In this series of 3 educational modules with accompanying downloadable slidesets, CCO's expert oncology faculty members discuss the use of targeted agents as well as the utility of the tumor microenvironment as a therapeutic target.

• 2008 American Society of Clinical Oncology Annual Meeting *
  
  
• 2008 Genitourinary Cancers Symposium*
  
  
• 2008 Gastrointestinal Cancers Symposium*
  
  
• 2007 American Society of Hematology Annual Meeting*
  
  
• 2007 San Antonio Breast Cancer Symposium*
  
  
  

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Adjuvant HER2-Positive Cancer: Integrating Prognostic Tools and Clinical Advances to Optimize Treatment

• Current Clinical Data on Adjuvant Therapy for HER2-Positive Breast Cancer
• Estimating Benefit and Prognosis With Adjuvant Therapy for HER2-Positive Breast Cancer
• Treatment of a 32-Year-Old Patient With HER2-Positive Breast Cancer
• Treatment of Breast Cancer in a 64-Year-Old Black Female With Multiple Positive Lymph Nodes
• Assessing Breast Cancer Prognosis and Applications for Clinical Practice

Research Priorities in Colorectal Cancer: Recommendations of the Scientific Leadership Council in GI Cancer of the Coalition of Cancer Cooperative Groups Colorectal Cancer: Demographics and Screening

• Colorectal Cancer Prevention
• Colorectal Cancer Detection and Diagnosis
• Adjuvant Treatment for Rectal Cancer
• Adjuvant Treatment for Colon Cancer
• Advanced Colorectal Cancer and Novel Therapies

Breast Cancer

• Treatment of a 32-Year-Old Patient With HER2-Positive Breast Cancer
• Treatment of Breast Cancer in a 64-Year-Old Black Female With Multiple Positive Lymph Nodes
  
  

Cutaneous T-Cell Lymphoma

• Treatment of Early-Stage CTCL in a 56-Year-Old Black Male Patient
• Treatment of a 54-Year-Old Male With Tumor-Stage Mycosis Fungoides
• Treatment of Recurrent Folliculotropic Mycosis Fungoides in a 37-Year-Old Black Female Patient

Multiple Myeloma

• Anthracycline Therapy in a 55-Year-Old Man With Relapsed Multiple Myeloma
• Anthracycline Therapy in a 67-Year-Old Man With Multiple Myeloma Who Has Relapsed After ASCT
  

Topics

• Breast Cancer
• Gastrointestinal Cancer
• General Hematology
• Genitourinary Cancer
• Gynecologic Cancer
• Head and Neck Cancer
• Hematologic Malignancies
• Lung Cancer

Resources

• Advanced Search
• Case Challenges
• Live Events
• Slide Download Library
• Free Bookstore

FEATURED VIDEO SEGMENT
Expert Highlight: Breast Cancer

Kathy D. Miller, MD, provides an update on the top issues in adjuvant therapy including hormone therapy, bone loss treatments, and vitamin D status. She also discusses the impact of biologic agents targeting VEGF and EGFR on therapy for metastatic disease. Click here to start.

Lenalidomide Demonstrates Activity in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

Nonrandomized trial of lenalidomide in patients with relapsed/refractory NHL shows efficacy and acceptable toxicity profile

Click here for related Capsule Summaries.

Click here for the more slides.

Click here to visit the bookstore.

Click here for more cases.